Elacestrant trials for Breast cancer

All Elacestrant trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Elacestrant for Breast cancer

• A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
  NCT07766018 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 562 locations
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• Circulating Tumor DNA
  NCT06923527 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
  NCT06075953 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 28 locations
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
  NCT07198724 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
  NCT06382948 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
  NCT05982093 · Phase: Phase 2 · Ages: 35 Years and older · Sex: Female · 15 locations
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
  NCT05512364 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 112 locations
• Elacestrant in Advanced Triple Positive Breast Cancer
  NCT07612215 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
  NCT07563595 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 3 locations
• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
  NCT07242352 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
  NCT07222215 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 14 locations
• Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
  NCT06544577 · Phase: Not specified · Ages: 18 Years and older · Sex: Female · 1 location
• Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
  NCT05386108 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 86 locations

Common questions

How many trials study Elacestrant for Breast cancer?

16 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.